A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients

Breast

Volumn 23, Issue 4, 2014, Pages 435-438

  Nechushtan, Hovav ^a   Vainer, Gilad ^a   Stainberg, Hana ^a   Salmon, Asher Y ^a   Hamburger, Tamar ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cetuximab; EGFR; Taxanes; Triple negative breast cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERIBULIN; FLUOROURACIL; METHOTREXATE; MINOCYCLINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ACNE; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPHAGIA; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; LUNG FLUID; LUNG METASTASIS; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PLEURA FLUID; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SKIN DISEASE; SKIN METASTASIS; SKIN TOXICITY; SURVIVAL TIME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; CARCINOMA; CHEMISTRY; CLINICAL TRIAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902551186     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.03.003     Document Type: Article

References (12)

1. Engebraaten O., Vollan H.K., Borresen-Dale A.L. Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 2013, 183:1064-1074.
2. Gelmon K., Dent R., Mackey J.R., Laing K., McLeod D., Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol Off J Eur Soc Med Oncol/ESMO 2012, 23:2223-2234.
3. Voduc D., Nielsen T.O. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Clin Breast Cancer 2008, 8(Suppl.4):S171-S178.
4. Bertucci F., Finetti P., Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012, 12:96-110.
5. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl.4):S3-S8.
6. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
7. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. JNatl Cancer Inst 2004, 96:739-749.
8. Merlin J.L., Barberi-Heyob M., Bachmann N. Invitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol Off J Eur Soc Med Oncol/ESMO 2002, 13:1743-1748.
9. Ferraro D.A., Gaborit N., Maron R., Cohen-Dvashi H., Porat Z., Pareja F., et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 2013, 110:1815-1820.
10. Duchnowska R., Dziadziuszko R., Czartoryska-Arlukowicz B., Radecka B., Szostakiewicz B., Sosinska-Mielcarek K., et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009, 117:297-303.
11. Baselga J., Gomez P., Greil R., Braga S., Climent M.A., Wardley A.M., et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. JClin Oncol Off J Am Soc Clin Oncol 2013, 31:2586-2592.
12. Pirker R., Pereira J.R., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1):33-42. 10.1016/S1470-2045(11)70318-7.